Ki-67 and outcome in clinically localised prostate cancer:Analysis of conservatively treated prostate cancer patients from the trans-atlantic prostate group study

Berney, D. M., Gopalan, A., Kudahetti, S., Fisher, G., Ambroisine, L., Foster, C. S., Reuter, V., Eastham, J., Møller, H., Kattan, M. W., Gerald, W., Cooper, C. ORCID: https://orcid.org/0000-0003-2013-8042, Scardino, P. and Cuzick, J. (2009) Ki-67 and outcome in clinically localised prostate cancer:Analysis of conservatively treated prostate cancer patients from the trans-atlantic prostate group study. British Journal of Cancer, 100 (6). pp. 888-893. ISSN 0007-0920

Full text not available from this repository. (Request a copy)

Abstract

Treatment decisions after diagnosis of clinically localised prostate cancer are difficult due to variability in tumour behaviour. We therefore examined one of the most promising biomarkers in prostate cancer, Ki-67, in a cohort of 808 patients diagnosed with prostate cancer between 1990 and 1996 and treated conservatively. Ki-67 expression was assessed immunohistochemically, in two laboratories, by two different scoring methods and the results compared with cancer-specific and overall survival. The power of the biomarker was compared with Gleason score and initial serum prostate-specific antigen (PSA). Both methods showed that Ki-67 provided additional prognostic information beyond that available from Gleason score and PSA: for the semi-quantitative method, Δχ2 (1 d.f.)=24.6 (P=0.0001), overall survival χ2=20.5 (P=0.0001), and for the quantitative method, Δχ2 (1 d.f.)=15.1 (P=0.0001), overall survival χ2=10.85 (P=0.001). Ki-67 is a powerful biomarker in localised prostate cancer and adds to a model predicting the need for radical or conservative therapy. As it is already in widespread use in routine pathology, it is confirmed as the most promising biomarker to be applied into routine practice.

Item Type: Article
Additional Information: Funding Information: This study was supported by Cancer Research UK, The National Institute of Health (SPORE), The Koch Foundation, The NCRI and the Grand Charity of Freemasons and The Orchid Appeal.
Uncontrolled Keywords: active surveillance,biomarker,ki-67,prostate cancer,watchful waiting,oncology,cancer research,sdg 3 - good health and well-being ,/dk/atira/pure/subjectarea/asjc/2700/2730
Faculty \ School: Faculty of Medicine and Health Sciences > Norwich Medical School
Related URLs:
Depositing User: LivePure Connector
Date Deposited: 18 Jul 2022 12:30
Last Modified: 12 Aug 2022 05:42
URI: https://ueaeprints.uea.ac.uk/id/eprint/86459
DOI: 10.1038/sj.bjc.6604951

Actions (login required)

View Item View Item